Document:

Exhibit 10.1

EMPLOYMENT AGREEMENT 

 

This
EMPLOYMENT AGREEMENT (the “Agreement”) is by and between John Hollister, an individual residing in Los Angeles
County, California ("Executive") and NuLife Sciences Inc., formerly SmooFi Inc., a Nevada corporation (the “Company”)
made this 26th day of January, 2017, the first day of the Initial Term, as defined below, but effective as of the 17th day of October,
2016, the date the Services (as defined herein) were first rendered (the “Effective Date).

 

WHEREAS, the
Company has recently acquired the assets of a private company, consisting

primarily of Patents
and rights to new Intellectual Property and technology related to the business of organ transplants (collectively, the “Proprietary
Organ Transplant Procedures”) together with other forms of new life science technologies (the “Asset Acquisition”):
and

 

WHEREAS,
Executive has over 25 years of experience in the Healthcare industry and life science based business management; and,

 

WHEREAS,
Executive has been active since the Effective Date assisting the Company with its due diligence on the Asset Acquisition, up
through and following the Closing of the Asset Acquisition by the Company (the “Pre-Closing Period”), and following
the Pre-Closing Period joining the Company as its full time Chief Executive Officer, to supervise, shepherd and implement the development
and monetization of the Acquired Assets, and developing a budget and managing such budget for the Company’s wholly-owned
subsidiary, NuLife Bio Med Inc. (“BioMed”) to enable the Company to pay the costs and expenses of resuming the remaining
number of animal trials (“Animal Trials”) necessary to enable the Company to apply for Clinical Human Trials; and,

 

WHEREAS,
the Company wishes to employ Executive as a full-time employee in the capacity of its Chief Executive Officer and, subject
to majority shareholder consent, serve on the Company’s Board of Directors. The duties of the Executive, among others, shall
include the performance of all of the duties typical of the office held as described in the bylaws of the Company and such other
duties involving the recently acquired patent and License for the Proprietary Organ Transplant Procedures, and other projects as
may be assigned by the Board of Directors, more fully described in “Section 1. Engagement” below.

 

NOW,
THEREFORE, in consideration of the mutual promises, covenants and agreements contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and Executive agree as follows:

 

1.       Engagement

 

The Company hereby
engages Executive to provide overall supervision, guidance and resolution of delays and/or problems encountered with respect to
all of the Company’s development of the assets, technology and development of the Proprietary Organ Transplant Procedures
derived from the patents and Licenses described generally in the Exhibit “A” to the Asset Purchase agreement dated
October 3, 2016 between the Company and GandTex LLC, a Texas Limited Liability

Company (“GandTex”), including but not limited to:

 

A) The development
of a realistic and well researched budget and organizational timelines for completing the remaining pre-Clinical (Animal) Trials
..

 

B) The development
and successful execution of the plan for commercializing the Proprietary Organ Transplant Procedures.

 

C) Working with the
CFO, and others as necessary, to assist the Company in raising the necessary capital to successfully build the Company.

 

D) Identifying the
need for and timing of critical staff and/or consultants to ensure a successful commercialization.

    	 

    	 

    

 

E) Inform and gain
support from the Board for plans and execution.

 

F) Represent the Company
in all investor, public interviews and professional settings.

 

G) Serve as the Commercial
representative for the Company until such time a staff person is added to manage this responsibility.

 

H) Make certain that
organizational timelines are both realistic and achieved.

 

I) Execute all
other duties customarily assigned to the CEO at the appropriate lifecycle stages of the Company.

 

It
is mutually agreed that Executive's duties may be reasonably modified from time to time at the discretion of the Company’s
Board of Directors. Executive shall devote his entire productive time, ability and attention to the business of the Company and
shall perform all duties in a professional, ethical and businesslike manner. Executive will not, during the term of this Agreement,
directly or indirectly engage in any other business, either as an Executive, employer, consultant, principal, officer, director,
advisor, or in any other capacity, either with or without compensation, without the prior written consent of Company’s Board
of Directors. Collectively, Executives duties referred to in this paragraph 1. are referred to as the “Services”.

 

Compensation 

 

Compensation
to Executive for the Services provided pursuant to this Agreement shall consist of the following:

 

A) Monthly Compensation.
As compensation for the Services, beginning the date hereof, during the Initial Term (as defined below) (a) the Company will pay
Executive $ 10,000/month until the Company has at least $500,000 available for the continued pursuit of the procedures and related
expenses to the development of the Proprietary Organ Transplant Procedures in the bank, with a reasonable reserve for the needs
of the Company to enable the Company to maintain sufficient working capital to retain the personnel and other services necessary
to the Company to remain in compliance with its accounting, audit and other related filing requirements pursuant to the Securities
Exchange Act of 1934 (the “’34 Act”) for the ensuing fiscal quarter increasing to (b) $20,000/month when the
Company has sufficient uncommitted funds in its account to fund its wholly-owned subsidiary, NuLife BioMed Inc. (“BioMed”)
through the Animal Trials as set out in the attached Projected Cash Requirements, and (c) if the Company is successful in raising
an amount that equals or exceeds Two Million Dollars ($2,000,000) so that it meets or exceeds the Projected Cash Requirements then
Executive’s salary will increase to $3 0,000/month. The Company will make up the difference between what Executive receives
each quarter Ninety Thousand Dollars ($90,000) with stock out of the Non-Qualified Employee Incentive Stock Compensation Plan,
issued at the end of each fiscal quarter based upon the closing price of the Company’s shares on the last day
of each quarter

 

B)
Options. The Company shall issue to Executive, or his designee, options (“Option”) to acquire up to One Million
Five Hundred Thousand (1,500,000) shares of the Company’s Common Stock (the “Option Shares”). Each Option shall
vest as to Five Hundred Thousand (500,000) shares at the conclusion of each of the three (3) stages identified in paragraph A (a),
A(b) and A (c) above. The Option Agreement and shall be deemed granted as at the Effective Date, and shall continue to be in force
and exercisable for the term of this Agreement, and any Extension Period (as defined below),

 

C.
Further Adjustment To Monthly Salary. Upon completion of a successful animal study, defined as meeting the primarendpoint,
and the successful raising of a minimum of Four Million Dollars ($4,000,000), the monthly salary will be adjusted to
$35,000.

    	 

    	 

    

 

D.
Health Benefits. The Company shall provide usual and customary health benefits for the Employee. At the time when finances permit,
the benefits will be extended to cover the Employee and their dependents, consistent with the policy of the Company.

 

E. Other Compensation,
(e.., bonuses and stock) as may be agreed upon based upon current budget and performance of that portion of the Company’s
business under the supervision of the Executive.

 

Term of Engagement.

 

This Agreement
shall have an initial term (“Initial Term”) ending upon earlier of (a) unsuccessful Animal Trials, (b) failure to obtain
FDA approval to proceed to Clinical Trials with procedures conducted on human beings, or (c) the third anniversary of the date
hereof (the “Term of Services”). By mutual agreement between Executive and the Company, this Agreement may be modified,
amended and the Term of Services extended (an “Extension Period”), (d) Executive’s resignation by written notice
as set forth in paragraph 10 below, or (e) removal of Executive by action of the Company’s Board of Directors for Cause (the
“Service Termination Date”).

 

Time Obligation 

 

Executive shall devote
his full time and attention to the business of the Company. Executive shall have Thirty (30) days per year of vacation during the
Initial Term of this Agreement and any extensions hereof, unless mutually agreed in writing between the Company’s Board of
Directors and Executive.

 

Representations
and Covenants of Executive and Company to each Other. 

 

Executive
and Company shall each comply with all rules and regulations of any domestic and/or foreign regulatory authorities which may be
applicable to the activities of Executive and Company.

 

Furthermore,

 

A) Executive shall
comply with all reasonable policies, practices and procedures established by Company.

 

B)
Executive and Company represent that none of the events described below have occurred during the past ten (10) years with respect
to Executive and Company or any of their agents or Executives: (i) a petition under any foreign or federal bankruptcy laws or any
foreign or state insolvency law was filed by or against, or a receiver or fiscal agent was appointed by a court for the business
or property of, such person, any partnership in which either was a general partner (or an executive officer of a general partner)
at or within two (2) years before the time of such filing, or any corporation or business association of which either was an executive
officer at or within two (2) years before the time of such filing; (ii) such person was convicted in a criminal proceeding or is
a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); (iii) such person was
the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
permanently or temporarily enjoining it from or otherwise limiting, the following activities: engaging in any type of business
or practice; engaging in any activity in connection with the Proprietary Organ Transplant Procedure; (iv) such person was the subject
of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any federal or state authority barring, suspending
or otherwise limiting for more than sixty (60) days the right of such person to be engaged in any activity described in Section
(iii), or to be associated with persons engaged in any such activity.

 

    	 

    	 

    

Nondisclosure and Nonuse
of Confidential Information. 

 

During the term
of this Agreement, it may be necessary for Company to provide Executive with access to certain proprietary information including,
but not limited to, lists of Company's customers and vendors; inventory data; financial information; information about Company’s
operations; and attorney-client privileged information (collectively the "Proprietary Information"). Such information
is confidential and is considered a trade secret by Company. Executive shall: (a) not disclose the Proprietary Information to others;
(b) not use the Proprietary Information for any reason except as necessary for the performance of the Services;; (c) not copy or
otherwise produce any documents regarding the Proprietary Information, or divulge such documents to others; (d) upon the termination
of this Agreement, Executive shall promptly deliver to Company all documents, letters, notes, notebooks, reports and other materials
of a confidential nature relating to the business of Company which is in its possession or control; and (e) take additional reasonable
actions necessary to ensure the confidentiality of the Proprietary Information, including, without limitation, obtaining written
non-disclosure agreements from Executive, Executive’s agents and third parties to whom the Proprietary Information is disclosed.
Notwithstanding anything to the contrary that is contained in this Agreement, Executive and Company may disclose Proprietary Information
solely to the extent that: (a) Executive or the Company is authorized in writing to do so by the other; (b) disclosure is required
by any applicable law, in the reasonable opinion of legal counsel to the parties; (c) the Proprietary Information is otherwise
public information. Executive and Company will promptly notify each other in the event that any Proprietary Information is no longer
confidential. The obligations of confidentiality contained in this Section 6 shall survive the termination of this Agreement. Executive
and Company acknowledge and agree that the other party would be irreparably damaged in the event that the provisions
of this Section 6 were not performed in accordance with their respective terms or were otherwise breached and monetary damages
would not provide an adequate or sufficient remedy in such event. Accordingly, it is agreed that Company or Executive, as the case
may be, shall be entitled to equitable relief (e.g., injunctive relief and specific performance) to enforce the provisions contained
in this Section 6 in addition to any other remedy, including monetary damages, that may be available at law or in equity..

 

Agreement For Non-Compete.

 

Beginning
the Effective Date, because the Company is providing Executive with access to Proprietary Information, and because any activity
by Executive in competition with the Company would inevitably cause Executive to disclose or utilize such Proprietary Information
to the detriment of the Company, Executive agrees that, during the term of this engagement, and for a period of one year commencing
on the date this Agreement terminates. Executive shall not, directly or indirectly, solicit, call upon, contact in any manner or
conduct any business with, regardless of who initiated the contact and regardless of the geographic location, any customer or vendor
of Company or any subsidiary or affiliate thereof for the purpose of providing or buying in any manner any computer products. The
foregoing limitations do not preclude Executive or its Executives from subsequently taking a position with a pharmaceutical product
manufacturer, or authorized distributor. Executive further agrees and covenants that during such period it will not, directly or
indirectly, (i) hire, or assist in or influence the hiring of, any Executive of Company or any subsidiary or affiliate thereof,
without the prior written consent of Company, or (ii) induce any Executive of Company or any subsidiary or affiliate thereof, to
resign or sever his or her employment relationship with Company or any subsidiary or affiliate thereof. Executive covenants that
it shall not at any time encourage or induce any customer of Company to sever its relationship with Company. Executive and the
Company acknowledge and agree that the Company would be irreparably damaged in the event that the Services were not performed in
accordance with the usual and customary oversight and management of the development of the technology and process covered by the
Patent, and monetary damages would not provide an adequate or sufficient remedy in such event. Accordingly, it is agreed that the
Company shall be entitled to equitable relief (e.g., injunctive relief and specific performance) to enforce the provisions contained
in this Section 6 in addition to any other remedy, including monetary damages, that may be available at law or in equity.

 

    	 

    	 

    

Restriction on Post-Employment
Compensation. 

 

For
a period of one (1) year after the end of the Initial Term and any Extension Periods, Executive shall not control, consult to or
be employed by any business similar to that conducted by the Company, either by soliciting any of its accounts or by operating
taking a position as consultant, executive officer or Director of a current competitor or an entity or organization attempting
to replicate, or use as the benchmark, the Proprietary Organ Transplant Procedure and any other techniques developed by the Company
derived by the use of one or more of the Acquired Assets, or subsequent patents or processes which are in any way derivatives of
the Acquired Assets.

 

Assistance
in Litigation. Executive shall upon reasonable notice, furnish such information and proper assistance to the Company as it
may reasonably require in connection with any litigation in which it is, or may become, a party either during or after employment.

 

Effect
of Prior Agreements. This Agreement supersedes any prior agreement between the Company or any predecessor of the Company and
the Executive, excepts that this Agreement shall not affect or operate to reduce any benefit or compensation inuring to the Executive
of a kind elsewhere provided and not expressly provided in this Agreement.

 

Costs and Expenses.

 

All third party and
out-of-pocket expenses incurred by Executive in the performance of the Services shall be paid by the Company, or if paid by Executive
on behalf of the Company then reimbursed by the Company. Reimbursement of costs and expenses shall be made within ten (10) days
of receipt by the Company of Executive’s written request for reimbursement; provided, however, that the Company must
approve in advance all such expenses in the aggregate in excess of $500 in any one (1) month, except for attending properly noticed
meetings of the Company’s Board of Directors, provided Executive is a member of the Company’s Board or a Board of Directors
of one of the Company’s subsidiaries.

 

Place of Services

 

Unless
otherwise mutually agreed by Executive and the Company, the Services provided by Executive hereunder will be performed at the offices
of the Company or its respective subsidiary, or, at such other location as may be required for Executive to provide the Services.
Failing to mutually agree on the place of Services this Agreement shall automatically terminate without penalty to either the Company
or Executive.

 

Executive an Employee.

 

Executive is providing
the Services as an employee of the Company, or of one of the entities affiliated with the Company. The Company or any such affiliated
entity may be required to pay or withhold any taxes or make any other payment with respect to fees payable to Executive, which
will be withheld from any sum due Executive.

 

Termination 

 

This
Agreement may be terminated prior to the expiration of the Initial Term upon the earlier of (a) thirty (30) days following receipt
by Executive of written notice by the Company to Executive to terminate this Agreement for Cause, or (b) thirty (30) days following
receipt by the Company of written notice by Executive to terminate this Agreement, for any reason. For the purpose of this Agreement
the term “Cause” shall mean:

 

A)       As
to Executive;

 

i) Executive is unable
to provide the Services as set forth herein for thirty (30) consecutive days because of illness, accident, or other incapacity;

    	 

    	 

    

 

ii)
Executive breaches or neglects the duties reasonably requested by a majority of the members of the Company’s Board of Directors
for any of the following; (a) failure by Executive to use his best efforts to begin the Animal on or
before June 30, 2017 , or (b) in the event the Animal Trials at any time indicate that the Proprietary Organ Transplant Procedure
should be terminated or delayed due to the lack of the necessary working capital or failures of the subject animal surgeries indicating
that the Proprietary Organ Transplant is not likely to obtain FDA approval to proceed to Clinical Trials, and the Board of Directors
determines that it is the best interest of the Company to abandon further Animal Trials, or actually fails to obtain FDA approval
to proceed to Clinical or (c) the third anniversary of the date hereof (the “Term of Services”); or,

 

iii) Executive breaches
a material term of this Agreement; or

 

iv) Executive files
a petition in a court of bankruptcy, or is adjudicated a bankrupt; or,

 

v) Executive is charged
by the Securities and Exchange Commission (the “SEC”), or any other domestic or foreign regulatory to a felony or misdemeanor
involving fraud, embezzlement, theft or dishonesty or other criminal conduct.

 

B)       As
to the Company:

 

i)
If the Company breaches this Agreement or fails to (a) make any payments to Executive of the Monthly Compensation as set forth
in Paragraph 2, or any other fees as required pursuant to this Agreement, for any reason except due to the lack of sufficient working
capital to retain the personnel and other services necessary to the Company to remain in compliance with its accounting, audit
and other related filing requirements pursuant to the ’34 Act) for the ensuing fiscal quarter, (b) issue the Option Shares
to Executive upon exercise by Executive, or (3c provide information reasonably requested by Executive in the course of providing
the Services; or

 

ii) If the Company
ceases business, or if the Company sells a controlling interest to a third party or agrees to a consolidation or merger of itself
with or into another corporation other than as part of a financing transaction, or sells substantially all of its assets to another
corporation, entity or individual; or

 

iii)
If the Company has a receiver appointed for its business or assets, or otherwise becomes insolvent or unable to timely satisfy
its obligations in the ordinary course of business, or if either the Company makes a general assignment for the benefit of creditors,
has instituted against it any bankruptcy proceeding for reorganization for rearrangement of its financial affairs, files a petition
in a court of bankruptcy, or is adjudicated a bankrupt; or

 

iv) If any of the disclosures
made by the Company herein, or subsequent hereto, are determined to be materially false or misleading.

 

In the event this
Agreement is terminated prior to the expiration of the Initial Term of Service by the Company for Cause, the Company has no obligation
to provide any severance. In the event this Agreement is terminated prior to the expiration of the Initial Terra of Service by
the Company without Cause, the Company then current salary, then the Company shall pay Executive a severance payment equal to three
(3) months of his then current salary, in cash and stock as the then current situation dictates.

 

    	 

    	 

    

Representations
and Warranties of the Company 

 

The Company represents
and warrants to Executive that;

 

A) Corporate
Existence. The Company is a corporation duly organized, validly existing, and in good standing under the laws of the State
of Nevada and California, with power to own property and carry on its business as it is now being conducted.

 

B) No Conflict.
This Agreement has been duly executed by the Company and the execution and performance of this Agreement will not violate, or
result in a breach of, or constitute a default in any agreement, instrument, judgment, decree or order to which the Company is
a party or to which the Company is subject, nor will such execution and performance constitute a violation or conflict of any
fiduciary duty to which the Company is subject.

 

C) Full Disclosure.
The information concerning the Company provided to Executive pursuant to this Agreement is, to the best of the Company's knowledge
and belief, complete and accurate in all material respects and does not contain any untrue statement of a material fact or omit
to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading.
Further, information as to the Company’s financial condition, historical share prices and trading volume, and corporate history
can be found at www.otcmarkets.com.

 

D) Date of Representations
and Warranties. Each of the representations and warranties of the Company set forth in this Agreement is true and correct at
and as of the date of execution of this Agreement.

 

Miscellaneous 

A) Authority.
Executive and those executing this Agreement on behalf of the Company represent that they are duly authorized to do so, and that
each has taken all requisite action required by law or otherwise to properly allow such signatories to execute this Agreement.

 

B) Subsequent
Events. Executive and the Company each agree to notify the other parties if, subsequent to the date of this Agreement, one
of the parties incurs obligations which could compromise its efforts and obligations under this Agreement.

 

C) Amendment.
This Agreement may be amended or modified at any time and in any manner only by an instrument in writing executed by the parties
hereto.

 

D)
Further Actions and Assurances. At any time and from time to time, each party hereto agrees, at its expense, to take such
action and to execute and deliver documents as may be reasonably requested or necessary to effectuate the purposes of this Agreement.

 

E)
Waiver. Any failure of any party to this Agreement to comply with any of its obligations, agreements, or conditions hereunder
may be waived in writing by the party to whom such compliance is owed. The failure of any party to this Agreement to enforce at
any time any of the provisions of this Agreement shall in no way be construed to be a waiver of any such provision or a waiver
of the right of such party thereafter to enforce each and every such provision. No waiver of any breach of or non-compliance with
this Agreement shall be held to be a waiver of any other or subsequent breach or noncompliance.

 

F)
Assignment. Neither this Agreement nor any right created by it shall be assignable by any party hereto without the prior
written consent of the other parties.

    	 

    	 

    

 

G)
Notices. Any notice or other communication required or permitted by this Agreement
must be in writing and shall be deemed to be properly given when delivered in person to an officer of the other party when deposited
for transmittal by certified or registered mail, postage prepaid, or when sent by facsimile, “email” or other electronic
transmission with proof of delivery, addressed as follows:

 

To the Company:

NuLife
Sciences Inc

2618 San Miguel,
Suite 203

Newport Beach,
California 92660 Telephone:

Facsimile:

Email:

 

To Executive: 

John
Hollister

 

 

Telephone:

Facsimile:

Email:

 

or
to such other person or address designated in writing subsequent to the date hereof by the Company or Executive to receive notices.

 

H)
Headings. The sections and subsection headings in this Agreement are inserted for convenience only and shall not affect
in any way the meaning or interpretation of this Agreement.

 

I)
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California,
applicable to the performance and enforcement of contracts made within such state, without giving effect to the law of conflicts
of laws applied thereby. In the event that any dispute shall occur between the parties arising out of or resulting from the construction,
interpretation, enforcement or any other aspect of this Agreement, the parties hereby agree to accept the exclusive jurisdiction
of the Courts of the State of California sitting in and for the County of Orange. In the event either party shall be forced
to bring any legal action to protect or defend its rights hereunder, then the prevailing party in such proceeding shall be entitled
to reimbursement from the non-prevailing party of all fees, costs and other expenses (including, without limitation, the actual
expenses of its attorneys) in bringing or defending against such action.

 

J)
Termination of Any Prior Agreements. Effective the date hereof all rights of the Company and Executive related to any other
agreement entered into between the Company and Executive prior to the Effective Date hereof, whether written or oral, is hereby
terminated.

 

K) Time is of the
Essence. Tune is of the essence of this Agreement and of each and every provision hereof.

 

L)
Binding Effect. This Agreement shall be binding upon the parties hereto and inure to the benefit of the parties, their respective
heirs, administrators, executors, successors, and assigns.

 

    	 

    	 

    

M)
Entire Agreement. This Agreement contains the entire agreement between the parties hereto and supersedes any and all prior
agreements, arrangements, or understandings between the parties relating to the subject matter of this Agreement. No oral understandings,
statements, promises, or inducements contrary to the terms of this Agreement exist. No representations, warranties, covenants,
or conditions, express or implied, other than as set forth herein, have been made by any party.

 

N) Severability.
If any part of this Agreement is deemed to be unenforceable the balance of the Agreement shall remain in full force and effect.

 

O)
Counterparts: Facsimile. An original of this Agreement may be executed simultaneously in three or more executed facsimile,
telecopy or other electronic reproductive counterparts, each of which shall be deemed an original, or facsimile, telecopy or other
electronic reproductive counterparts, shall constitute one and the same instrument, and delivery of such shall be considered valid,
binding and effective for all purposes. At the request of any party hereto, all parties agree to execute an original of this instrument
as well as any facsimile, telecopy or other reproduction hereof.

 

P)
Consolidation or Merger. Subject to the provisions hereof, in the event of a sale of the stock, or substantially all of
the stock of the Company, or consolidation or merger of the Company with or into another corporation or entity, or the sale of
substantially all of the operating assets of the Company to another corporation, entity or individual, the Company’s rights
and obligations under this Agreement to its successor-in-interest shall be deemed to have acquired and assumed by such successor-in-interest;
provided, however, that in no event shall the duties and Services of Executive provided for herein, or the responsibilities, authority
or powers commensurate therewith, change in any material respect as a result of such sale of stock, consolidation, merger or sale
of assets.

 

    	 

    	 

    

IN
WITNESS WHEREOF, the parties have executed this Agreement effective the date first written above.

 

The "Company"

NuLife Sciences Inc.

 

 

 

By:____________________________

Name: Title:

"Executive"
John Hollister

 

 

By:____________________________

Name: Title:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 

    	 

    

EXHIBIT “A”

To The Employment
Agreement 

Between

 

NuLife Sciences
Inc.

 

And

 

John Hollister

 

The OptionExhibit 10.2

OPTION AGREEMENT

 

THIS OPTION AGREEMENT (“Option”)
is entered into effective this 15th day of May, 2017, by and between John Hollister, an individual residing in Los Angeles
County, California (“Optionee”) and NuLife Sciences Inc., a publicly held Nevada corporation (the “Company”).

 

WHEREAS, the Company and
Optionee are parties to an Employment Agreement date May 15, 2017 (the “Employment Agreement”); and,

 

WHEREAS, in consideration
for and as an inducement for Optionee entering into the Employment Agreement, and Optionee’s efforts beginning on October
17, 2016 preceding the effective date of the Employment Agreement, the Company hereby agrees to grant to Optionee options to purchase
shares of its $.001 par value common stock (“Common Stock”).

 

NOW, THEREFORE, for and
in consideration of the mutual promises herein, and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, and subject to the terms and conditions set forth below, Optionee and the Company agree as follows:

 

		1.	The Option

 

In consideration for Optionee entering
into the Employment Agreement, the Company hereby agrees and does grant to Optionee, to become effective and vest to Optionee upon
execution hereof, the option to acquire up to One Million Five Hundred Thousand (1,500,000) shares of the Company’s Common
Stock (the “Option Shares”), issuable from the Company’s 2016 Non-Qualified Incentive Stock Plan (the “Plan”).

 

		2.	Option Term and Exercise Price 

 

		A.	Term of Option. Subject to the terms of this Option, Optionee
shall have the right to exercise the Option in whole or in part, until the third (3rd) anniversary of the Company’s
execution hereof.

 

		B.	Exercise Price .  The exercise price per share of
the Common Stock under this Option shall _________ Cents ($.__) per share, which represents One Hundred Ten percent (110%) of the
ten (10) day trailing average closing Bid price of such shares on October 17, 2016, subject to adjustment hereunder (the “Exercise
Price”). 

 

		C.	Mechanics of Exercise. The Option shall vest following three
(3) events in accordance with the terms of the Employment Agreement, with the number of Options Shares available to be exercised
each event limited to Five Hundred Thousand (500,000) shares. Exercise of the purchase rights as to the Option may be made, in
whole or in part, by delivery to the Company of a duly executed facsimile copy of the Notice of Exercise Form annexed  hereto
(or such other office or agency of the Company as it may designate by notice in writing to the  registered Optionee at the
address of such Optionee appearing on the books of the Company); and, within Three (3) Trading Days of the date said Notice of
Exercise is delivered to the Company, the Company shall have received  payment of the aggregate Exercise Price of the
shares thereby purchased by wire transfer or cashier’s check drawn on a United States bank.  Notwithstanding anything
herein to the contrary, the Optionee shall not be required to physically surrender this Option to the Company until the Optionee
has purchased all of the Option Shares available hereunder and the Option has been exercised in full, in which case, the Optionee
shall surrender this Option to the Company for cancellation within ten (10) 

    	 	1	 

    	 

    

 

Trading Days following Optionees’s
receipt of the balance of the Option Shares so exercised.  Partial exercises of this Option resulting in purchases of
a portion of the total number of Option Shares available hereunder shall have the effect of lowering the outstanding number of
Option Shares purchasable hereunder in an amount equal to the applicable number of Option Shares purchased.  The Optionee
and the Company shall maintain records showing the number of Option Shares purchased and the date of such purchases.  The
Company shall deliver any objection to any Notice of Exercise Form within three (3) business days of receipt of such notice.  In
the event of any dispute or discrepancy, the records of the Optionee shall be controlling and determinative in the absence of manifest
error. The Optionee and any assignee, by acceptance of this Option, acknowledge and agree that, by reason of the provisions of
this paragraph 2, following the purchase of a portion of the Option Shares hereunder, the number of Option Shares available for
purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

		3.	Mechanics
of Exercise

 

Exercise of the
purchase rights represented by this Option may be made, in whole or in part during the Term of this Option by delivery to the Company
of a duly executed facsimile copy of the Notice of Exercise Form attached hereto (or such other office or agency of the Company
as it may designate by notice in writing to the registered Optionee at the address of such Optionee appearing on the books of the
Company). Upon receipt of Optionee’s Notice of Exercise the Company shall immediately cause the delivery of the Option Shares,
to be issued from the Stock Plan, so purchased to Optionee, or in such name or names as Optionee may designate. In the event the
Option is exercised in respect of less than all of the Option Shares purchasable on such exercise at any time prior to the date
of expiration hereof, the remaining Option Shares shall continue to be subject to adjustment as set forth herein; provided however,
that within five (5) Trading Days of the date said Notice of Exercise is delivered to the Company, the Company shall have received  payment
of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s check drawn on a United States
bank

 

Notwithstanding anything herein to
the contrary, the Optionee shall not be required to physically surrender this Option to the Company until the Optionee has purchased
all of the Option Shares available hereunder and the Option has been exercised in full, in which case, the Optionee shall surrender
this Option to the Company for cancellation within ten (10) Trading Days following Optionees’s receipt of the balance of
the Option Shares so exercised.  Partial exercises of this Option resulting in purchases of a portion of the total number
of Option Shares available hereunder shall have the effect of lowering the outstanding number of Option Shares purchasable hereunder
in an amount equal to the applicable number of Option Shares purchased.  The Optionee and the Company shall maintain
records showing the number of Option Shares purchased and the date of such purchases.  The Company shall deliver any
objection to any Notice of Exercise Form within one (1) Business Day of receipt of such notice.  In the event of any
dispute or discrepancy, the records of the Optionee shall be controlling and determinative in the absence of manifest error. The
Optionee and any assignee, by acceptance of this Option, acknowledge and agree that, by reason of the provisions of paragraph 2
or 3, following the purchase of a portion of the Option Shares hereunder, the number of Option Shares available for purchase hereunder
at any given time may be less than the amount stated on the face hereof.

 

		4.	Adjustment
of Option Shares

 

The number of Option Shares purchasable
pursuant to this Option shall be subject to adjustment from time to time upon the happening of certain events, as follows:

    	 	2	 

    	 

    

 

 

		A.	Adjustment for Recapitalization. In the event the Company
shall (a) subdivide its outstanding shares of Common Stock, or (b) issue or convert by a reclassification or recapitalization of
its shares of Common Stock into, for, or with other securities (a “Recapitalization”), the number of Option Shares
purchasable hereunder immediately following such Recapitalization shall be adjusted so that Optionee shall be entitled to receive
the kind and number of Option Shares or other securities of the Company measured as a percentage of the current issued and outstanding
shares of Company’s Common Stock as of the date hereof, which it would have been entitled to receive had such Option been
exercised immediately prior to the happening of such event or any record date with respect thereto; provided however that, notwithstanding
anything in this Option or the Employment Agreement to the contrary, the number of Option Shares shall not be reduced or affected
in any way as a result of a reverse stock split either by a reduction of the number of Option Shares or an increase in the Option
Price (the “Repricing”), unless such Repricing is mutually agreed upon in writing between Optionee and the Company
prior to any adjustment.

 

		B.	Preservation of Purchase Rights Under Consolidation. Subject
to paragraph 4A. above, in case of any Recapitalization or any other consolidation of the Company with or merger of the Company
into another corporation, or in case of any sale or conveyance to another third party (a “successor”) of the property
of the Company, in its entirety or substantially in its entirety, the Company shall, prior to the Closing of such transaction,
cause such successor or purchasing party, to acknowledge and assume in writing responsibility for the Company's obligations hereunder,
and to grant Optionee the right thereafter upon payment of the Option Price to purchase the kind and the greater of (a) the number
of Option Shares as stated here, or (b) an equivalent percentage of successor’s shares as the Option Shares now represent
to the Company’s total shares issued and outstanding or other securities and property of the successor, which Optionee would
have been entitled to receive after the happening of such consolidation, merger, sale or conveyance. The provisions of this paragraph
shall similarly apply to successive consolidations, mergers, sales or conveyances.

 

Notice of Adjustment.
Whenever the number of Option Shares purchasable hereunder is adjusted, as herein provided, the Company shall mail by first class
mail, postage prepaid, to Optionee notice of such adjustment or adjustments, and shall deliver to Optionee setting forth the adjusted
number of Option Shares purchasable and a brief statement of the facts requiring such adjustment, including the computation by
which such adjustment was made.

 

		5.	Assignment

 

The rights represented by this Option
may only be assigned or transferred by Optionee to an affiliate or retirement plan, or to a trust if affected as the result of
estate planning. For the purpose of this Option, the term "affiliate" shall be defined as a family member or an enterprise
that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control of Optionee;
otherwise, this Option and the rights hereunder shall not be assigned. Any assignment or attempted levy against this Option or
the Option Shares, or the proceeds therefrom, shall void this Option in its entirety.

 

		6.	Registration of Option Shares

 

As soon as practical following the
date hereof as to the Option Shares, and as to an anticipated event giving rise to the obligation by the Company to issue to other
optionees serving as employees or advisors to the Company, The Common Stock comprising such all shares reserved

    	 	3	 

    	 

    

 

for option exercise under issued
Options shall be registered by the Company with the Securities and Exchange Commission under a Form S-8 or other applicable registration
statement, and the Company shall cause such registration statement to remain effective at all times while all such optionees have
the right to purchase Option Shares.

 

At Optionee 's election, all or any portion of the Option
Shares may be issued prior to registration in reliance on exemptions from registration provided by Section 4(2) of the Securities
Act of 193, as amended (the "'Act"), Regulation D of the Act, and applicable state securities laws.

 

		7.	Further Documentation

 

Each party hereto agrees to execute
such additional instruments and take such action as may be reasonably requested by the other party to affect the transaction, or
otherwise to carry out the intent and purposes of this Option.

 

		8.	Notices

 

All notices and other communications
hereunder shall be in writing and shall be sent by prepaid first class mail to the parties at the following addresses, as amended
by the parties with written notice to the other:

 

In the case of the Company:

NuLife Sciences Inc

Attn: Sean Clarke

1031 Calle Recodo Ste B

San Clemente CA 92673

Telephone: 1.949.973.0684

Email: info@nulifesciences.us

 

In the case of
Advisor:

John Hollister

 

 

Telephone:

Facsimile: ____________________

Email: ________________________

 

		9.	Governing Law

 

This Option was negotiated, and shall
be governed by the laws of California notwithstanding any conflict-of-law provision to the contrary.

 

		10.	Agreement

 

This Option sets forth the entire
understanding as to Optionee’s rights to purchase shares of the Company’s Common Stock, and no other prior written
oral statement or agreement related to Optionee’s right as to the Option Shares shall be recognized or enforced, save and
except the Employment Agreement.

    	 	4	 

    	 

    

 

 

		11.	Severability

 

If a court of competent jurisdiction
determines that any clause or provision of this Option is invalid, illegal or unenforceable, the other clauses and provisions of
the Option shall remain in full force and effect and the clauses and provisions which are determined to be void, illegal or unenforceable
shall be limited, so that they shall remain in effect to the extent permissible by law.

 

		12.	Headings

 

The section and subsection headings
in this Option are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Option.

 

		13.	Counterparts

 

This Option may be executed simultaneously
in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. A facsimile, telecopy or other reproduction of this instrument may be executed by one or more parties hereto and
such executed copy may be delivered by facsimile or similar instantaneous electronic transmission device pursuant to which the
signature of or on behalf of such party can be seen, and such execution and delivery shall be considered valid, binding and effective
for all purposes. At the request of any party hereto, all parties agree to execute an original of this instrument as well as any
facsimile, telecopy or other reproduction hereof.

 

IN WITNESS WHEREOF, the parties have
executed this Option the day and year first written above.

“Optionee”

 

________________________

John Hollister

 

 

 

The “Company”

NuLife Sciences Inc.

a Nevada corporation

 

By _____________________

Name:

Title:

 

 

 

 

 

 

 

 

 

 

 

 

    	 	5	 

    	 

    

 

NOTICE OF
EXERCISE 

 

TO: NuLife Sciences Inc.

 

(1)  The undersigned
hereby elects to purchase ______________________ (___________) Option Shares of the Company pursuant to the terms of the attached
Option (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)  Payment shall
take the form of a cashiers check or wire transfer, at the discretion of Optionee, in lawful money of the United States; or

 

(3)  Please issue
the Option Shares to the following:

 

(__) DWAC Account Number
as follows, or (__) by physical delivery of a certificate or certificates to the following address:

 

_______________________________

 

_______________________________

 

_______________________________

 

_______________________________

 

 

(4)   Accredited Investor .  The
undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as
amended.

 

[SIGNATURE OF OPTIONEE]

 

___________________________

Name:

Title (if a Trust or other type of entity):

ate: __________________, __________

 

 

 

 

 

 

 

 

 

 

 

 

    	 	6	 

    	 

    

 

ASSIGNMENT
FORM 

 

(To assign the foregoing Option, execute this
form and supply required information.

Do not use this form to exercise the Option
)

 

 

FOR VALUE RECEIVED, the undersigned, holder
of the Option Agreement between the undersigned and NuLife Sciences Inc. dated ___________, 20____, hereby assigns all, or that
portion of the Option, and all rights evidenced thereby, representing ___________________(_____________) Option Shares (as defined
in the Option) , to:

 

______________________________________________________________________________

 

whose address is: _____________________________________________________________________________.

 

__________________________________, ________________,
_____________

 

Dated:  ______________, _______

 

 

Optionee’s Signature:   _______________________________________________

 

Optionee’s Address:     _______________________________________________

 

_____________________________, ________________,

 

__________________

 

 

 

 

 

 

 

Signature Guaranteed:  ___________________________________________

 

 

NOTE:  The signature to this Assignment Form must correspond
with the name as it appears on the face of the Option, without alteration or enlargement or any change whatsoever, and must be
guaranteed by a bank or trust company.  Officers of corporations and those acting in a fiduciary or other representative
capacity should file proper evidence of authority to assign the foregoing Option.

 

 

    	 	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]